Displaying 81 - 90 of 243
Alternative Name: Antiestrogen ICI 182780; Fulvestrant
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: No
Duration Type: Permanent
Delivery Method: Intrauterine
Developer: Femasys Inc
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium, APCOR R&M, Belgium
Development Stage: Regulatory
Development Phase: Limited Market Availability
Alternative Name: Fibroplant LNG14 (also LNG 20)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Stage: Regulatory
Development Phase: Limited Market Availability
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Meril Life Science Private Ltd
Development Stage: Marketed
Development Phase: Limited Market Availability
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Prosan International B.V.
Development Stage: Marketed
Development Phase: Limited Market Availability
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Injectable
Developer: University of Washington, Focused Scientific
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other
Development Stage: Compound ID/Selection
Development Phase: Discovery and Early Development
User: Female
Hormonal: Yes
Delivery Method: Injectable
Developer: University of Mumbai
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Sperm glycolytic enzyme
Target
Hormonal: No
Developer: University of North Carolina at Chapel Hill, NICHD
Development Stage: Target Validation
Development Phase: Discovery and Early Development

Pages

Displaying 61 - 70 of 70
User: Female
Hormonal: No
Developer: Rutgers University
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Other
Development Stage: Lead Optimization
Target
User: Male
Hormonal: No
Developer: Baylor College of Medicine, NICHD
Development Stage: Target Validation
Alternative Name: RISUG in the Fallopian Tube
User: Female
Hormonal: No
Duration Type: Permanent, Long-acting
Delivery Method: Fallopian Tube
Developer: Indian Institute of Technology, Kharagpur
Development Stage: Prototype Development
Alternative Name: Tripterygium wilfordii derivatives, including triptolide
User: Male
Hormonal: No
Developer: WHO, University of California at Los Angeles
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Permanent
Delivery Method: Intrauterine
Developer: FHI 360, GE Healthcare
Development Stage: Prototype Development
User: Female
Hormonal: Yes
Delivery Method: Vaginal, Other
Developer: University of Texas Health Science Center at San Antonio
Development Stage: Lead Optimization
Alternative Name: WEE1 HOMOLOG 2; WEE1B; WEE2 Kinase
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University, University of Minnesota
Development Stage: Lead Optimization
Alternative Name: Miglustat; N-butyldeoxynojirimycin (NB-DNJ)
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Oral
Developer: University of Washington, Oxford GlycoSciences
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: University of Nairobi
Development Stage: Lead Optimization

Pages

Displaying 1 - 10 of 121
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shandong Provincial Institute, China, Technology for Family Planning, China
Development Stage: Pre-clinical
Alternative Name: Inhibitors of Testicular Retinoic Acid Biosynthesis
User: Male
Hormonal: No
Duration Type: Long-acting, Short-acting
Delivery Method: Oral
Developer: University of Washington, University of Minnesota
Development Stage: Pre-clinical
Alternative Name: ARC; triple hormone contraceptive; Triple OC
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: ANI Pharmaceuticals, Pantarhei Bioscience
Development Stage: Phase II
Alternative Name: Suspensories
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Testicular
Developer: Centre Hospitalier Universitaire de Toulouse, France
Development Stage: Phase II
Alternative Name: LNG Biodegradable Implant for Contraception, Yale BDI
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: FHI 360, Yale University
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Peking University, Institute of Biomedical Engineering at Chinese Academy of Medical College
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR)
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: University of Washington
Development Stage: Pre-clinical
Alternative Name: BDADs
User: Female, Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: Focused Scientific, University of Washington
Development Stage: Pre-clinical
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal Gel
Developer: ReProtect Inc.
Development Stage: Phase III

Pages

Displaying 21 - 30 of 52
Alternative Name: GyneFix 330
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shenyang Liren Medical & Technological Co.
Development Stage: Marketed
Alternative Name: Copper IUD for Nulliparous Women, Smaller Copper IUD T380
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Implementos Plasticos, Ltd., Mexico City
Development Stage: SRA/WHO PQ Approved
Alternative Name: SCu300 Intrauterine Devices, empira™
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: OCON Medical Ltd.
Development Stage: SRA/WHO PQ Approved
Alternative Name: LNG Contraceptive IUS (LCS); LCS16
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Bayer HealthCare
Development Stage: SRA/WHO PQ Approved
Alternative Name: Zarin; Femplant; Trust; Sino-implant (II)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: FHI 360, Shanghai Dahua Pharmaceuticals, Ltd.
Development Stage: Marketed
Alternative Name: Levosert (U.K.); Erlacela (Portugal); Donasert (Romania); Avibela
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Actavis, Medicines360
Development Stage: SRA/WHO PQ Approved
Alternative Name: FC-Patch Low; Gestodene (GES) + ethinyl estradiol (EE) Patch
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: WHO HRP, Bayer HealthCare, Gedeon Richter Plc.
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: 7Med Industrie, France
Development Stage: Regulatory
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Mona Lisa N.V.
Development Stage: SRA/WHO PQ Approved

Pages

CSV